Annual General Meeting 2026 Date
Released
Released
Announcement PDF
ASX Announcement
Annual General Meeting 2026 Date
Melbourne, Australia; 15 September 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative
biotechnology company advancing dendrimer technology from the lab to the patient, today
announces, in accordance with ASX Listing Rule 3.13.1, that its 2026 Annual General Meeting (AGM)
will be held on Friday, 6 November 2026.
The Company notes that this announcement is being released later than the timing contemplated by
ASX Listing Rule 3.13.1 dueto an administrative oversight. This announcementshouldhave beenmade
on Friday, 11 September 2026. The Company will ensure compliance with Listing Rule 3.13.1 in future.
The closing date for receipt of nominations from persons wishing to be considered for election as a
director is Friday, 18 September 2026 (Closing Date). Nominations must be received in writing no later
than 5:00pm (AEST) on the Closing Date at the company’s registered office.
Details of the AGM will be provided in the Notice of Meeting, which will be issued in early October. As
in past years, the Chair’s address and CEO’s presentation will be shared with the market before the
commencement of the AGM.
About Starpharma
Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from
the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life
through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of
branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma’s portfolio ofdendrimer-based productsincludes clinical-stage DEP® (dendrimerenhanced product) assets, preclinical radiopharmaceutical
assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
Investor & Media Relations
Gabriella Hold
gaby@thecapitalnetwork.com.au
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations Officer and
Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford VIC 3067
Disclosure
This ASX announcement was
authorised for release by the
Company Secretary Mr Justin Cahill.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology
such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking
to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential
filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product
candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any
particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by,
among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government
regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and
general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and
business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary
materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments
or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to
product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing
contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past,
present or the future performance of any Starpharma product.
Share your feedback
Discover